<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675815</url>
  </required_header>
  <id_info>
    <org_study_id>D2EFT BodyComp</org_study_id>
    <nct_id>NCT03675815</nct_id>
  </id_info>
  <brief_title>Body Composition Sub-study of the D2EFT Trial</brief_title>
  <official_title>Body Composition Sub-study of the D2EFT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a
      randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line
      antiretroviral therapy (ART) in low-middle income countries. The sub-study will be offered to
      all D2EFT sites with access to DXA technology for whole-body composition analysis. Sites will
      offer the sub-study to consecutive clinic patients. Patients must be approached for
      participation and provide informed written consent prior to randomisation into D2EFT. This
      study will recruit approximately 300 patients. Allocation to one of three ART treatment
      regimens will follow the result of D2EFT randomisation. The study will investigate the role
      of contemporary ART on body composition and metabolic parameters by comparing over 96 weeks
      the effects of the D2EFT ART regimens. The primary endpoint will be assessed at week 48.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consenting participants will be randomised within the main D2EFT protocol to receive either
      ritonavir-boosted darunavir plus two nucleosides or dolutegravir plus two predetermined
      nucleosides (lamivudine or emtricitabine) or ritonavir-boosted darunavir plus dolutegravir.
      Enrolment into the sub-study is voluntary and not a requirement for enrolment into D2EFT.
      Parameters relevant to this study including demographics, arm of randomised ART, smoking
      status, body habitus and fasting lipid parameters and resting blood pressure at required time
      points will be collected as part of the main D2EFT study. Sub-study specific assessments
      performed at baseline and at weeks 48 and 96 include clinical and laboratory assessments,
      sample collection and dual-energy X-ray absorptiometry (DXA)-assessed whole-body composition.
      Consenting participants will have blood for storage collected at weeks 0, 48 and 96. The
      specimens will be used for future studies into treatment of HIV infection and immunity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean/median between-group change in waist-to-hip ratio</measure>
    <time_frame>at 48 weeks</time_frame>
    <description>umbilical waist and hip measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean/median between-group change in total-to-HDL cholesterol ratio</measure>
    <time_frame>at 48 weeks</time_frame>
    <description>total and HDL cholesterol plasma concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group change in total-to-HDL cholesterol ratio</measure>
    <time_frame>at 96 weeks</time_frame>
    <description>total and HDL cholesterol plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group change in waist-to-hip ratio</measure>
    <time_frame>at 96 weeks</time_frame>
    <description>umbilical waist and hip measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group change in body weight</measure>
    <time_frame>at week 48 and 96</time_frame>
    <description>body weight measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group change in maximum umbilical and hip measures</measure>
    <time_frame>at week 48 and 96</time_frame>
    <description>umbilical waist and hip measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group change in fasting lipid parameters</measure>
    <time_frame>at weeks 48 and 96</time_frame>
    <description>total, HDL, and LDL cholesterol and triglyceride plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group change in fasting glycaemic parameters</measure>
    <time_frame>at weeks 48 and 96</time_frame>
    <description>glucose, insulin, HbA1c concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group absolute change in limb fat assessed by DXA</measure>
    <time_frame>week 48 and 96</time_frame>
    <description>absolute change from baseline in limb fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group percentage change in limb fat assessed by DXA</measure>
    <time_frame>week 48 and 96</time_frame>
    <description>percentage change from baseline in limb fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group changes in regional body fat assessed by DXA</measure>
    <time_frame>week 48 and 96</time_frame>
    <description>regional = limb fat and truncal fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group changes in total body fat and lean tissue assessed by DXA</measure>
    <time_frame>week 48 and 96</time_frame>
    <description>total body fat and total lean tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group changes in bone mineral content assessed by DXA</measure>
    <time_frame>week 48 and 96</time_frame>
    <description>total bone mineral content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean/median between-group change in Body Image questionnaire scores</measure>
    <time_frame>weeks 48 and 96</time_frame>
    <description>NIAID Adult AIDS Clinical Trials Group Baseline and Follow-up questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion with Metabolic Syndrome</measure>
    <time_frame>week 0, and week 48 and 96</time_frame>
    <description>baseline prevalence and incidence at weeks 48 and 96</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean/median between-group change in serum biomarker concentrations</measure>
    <time_frame>weeks 48 and 96</time_frame>
    <description>biomarkers to be determined</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet + (N(t)RTIs) po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir + TDF + either 3TC or FTC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dolutegravir 50 mg oral tablet + TDF 300 mg oral tablet + either 3TC 300 mg oral tablet or FTC 200 mg oral capsule po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir + darunavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dolutegravir 50 mg oral tablet + darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet po qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir 800 MG Oral Tablet</intervention_name>
    <description>800 milligrams (mg) orally once daily for 96 weeks</description>
    <arm_group_label>Dolutegravir + darunavir</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>DRV, Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir 100 MG Oral Tablet</intervention_name>
    <description>100 mg orally once daily for 96 weeks</description>
    <arm_group_label>Dolutegravir + darunavir</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Norvir, RTV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N(t)RTIs</intervention_name>
    <description>Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection</description>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Nucleoside/nucleotide reverse transcriptase inhibitors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir 50 MG Oral Tablet</intervention_name>
    <description>50 mg orally once daily for 96 weeks</description>
    <arm_group_label>Dolutegravir + TDF + either 3TC or FTC</arm_group_label>
    <arm_group_label>Dolutegravir + darunavir</arm_group_label>
    <other_name>Tivicay, DTG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF 300 MG Oral Tablet</intervention_name>
    <description>300 mg orally once daily for 96 weeks</description>
    <arm_group_label>Dolutegravir + TDF + either 3TC or FTC</arm_group_label>
    <other_name>tenofovir disoproxil fumarate, Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3TC 300 MG Oral Tablet</intervention_name>
    <description>300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician</description>
    <arm_group_label>Dolutegravir + TDF + either 3TC or FTC</arm_group_label>
    <other_name>lamivudine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC 200 MG Oral Cap</intervention_name>
    <description>200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician</description>
    <arm_group_label>Dolutegravir + TDF + either 3TC or FTC</arm_group_label>
    <other_name>Emtriva, emtricitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfil the criteria for D2EFT randomisation

          -  Able to undergo DXA whole-body scanning

          -  Provide informed written consent for the D2EFT Body Composition Sub-study

        Exclusion Criteria:

          -  Unwilling to comply with the study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Polizzotto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Kirby Institute, UNSW Sydney</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dianne Carey, PhD</last_name>
    <phone>+61 2 9385 0908</phone>
    <email>dcarey@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univerity of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret CH Tan</last_name>
      <phone>+60379492622</phone>
      <email>margarettan455@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Iskandar S Raja Azwa, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>September 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

